Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model

Table 3

Total CVD SCORE at baseline and final (6-week) assessments.

Patient Group	Total CVD SCORE
	Baseline				6 weeks				Absolute Change				Percent Change
	Mean	SD	95% CI		Mean	SD	95% CI		Mean	SD	95% CI		Mean	SD	95% CI
			Lower	Upper			Lower	Upper			Lower	Upper			Lower	Upper
Hypertension	0.080	0.064	0.074	0.086	0.059	0.048	0.054	0.063	−0.021	0.032	−0.024	−0.018	−0.230	0.243	−0.253	−0.207
Diabetes	0.061	0.051	0.055	0.066	0.047	0.041	0.042	0.051	−0.014	0.024	−0.017	−0.012	−0.200	0.255	−0.227	−0.173
MS*	0.069	0.059	0.063	0.075	0.052	0.045	0.047	0.056	−0.017	0.028	−0.020	−0.014	−0.212	0.257	−0.238	−0.187
Smoking	0.077	0.070	0.067	0.087	0.056	0.051	0.049	0.063	−0.021	0.030	−0.025	−0.016	−0.254	0.214	−0.284	−0.223
Total	0.068	0.059	0.065	0.072	0.053	0.046	0.050	0.056	−0.015	0.028	−0.017	−0.013	−0.198	0.249	−0.215	−0.181

*MS: metabolic syndrome.